Cargando…

Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis

Background: We examined the real-world drug retention rate and safety data of Janus kinase inhibitors (JAKis) in elderly patients with rheumatoid arthritis (RA). Methods: This study enrolled 133 RA patients (≥65 years) with sufficient clinical data who were initiated with JAKis during the study peri...

Descripción completa

Detalles Bibliográficos
Autores principales: Temmoku, Jumpei, Miyata, Masayuki, Suzuki, Eiji, Sumichika, Yuya, Saito, Kenji, Yoshida, Shuhei, Matsumoto, Haruki, Fujita, Yuya, Matsuoka, Naoki, Asano, Tomoyuki, Sato, Shuzo, Migita, Kiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380728/
https://www.ncbi.nlm.nih.gov/pubmed/37510700
http://dx.doi.org/10.3390/jcm12144585
_version_ 1785080267672649728
author Temmoku, Jumpei
Miyata, Masayuki
Suzuki, Eiji
Sumichika, Yuya
Saito, Kenji
Yoshida, Shuhei
Matsumoto, Haruki
Fujita, Yuya
Matsuoka, Naoki
Asano, Tomoyuki
Sato, Shuzo
Migita, Kiyoshi
author_facet Temmoku, Jumpei
Miyata, Masayuki
Suzuki, Eiji
Sumichika, Yuya
Saito, Kenji
Yoshida, Shuhei
Matsumoto, Haruki
Fujita, Yuya
Matsuoka, Naoki
Asano, Tomoyuki
Sato, Shuzo
Migita, Kiyoshi
author_sort Temmoku, Jumpei
collection PubMed
description Background: We examined the real-world drug retention rate and safety data of Janus kinase inhibitors (JAKis) in elderly patients with rheumatoid arthritis (RA). Methods: This study enrolled 133 RA patients (≥65 years) with sufficient clinical data who were initiated with JAKis during the study period. These patients were divided into two groups: the very elderly group (≥ 75 years) and the elderly group (65 ≤ years < 75). The drug retention rates of JAKis were compared using Kaplan–Meier curves. Results: The discontinuation rates of JAKis were as follows: lack of effectiveness 27 (20.3%), adverse events (AEs) 29 (21.8%), and remission 2 (1.5%). There was no significant difference in the overall drug retention rate between the very elderly group (≥75 years) and the elderly group. Furthermore, the overall drug retention rates of JAKis were not affected by gender, methotrexate use, and anti-citrullinated protein/peptide antibody (ACPA) status. The discontinuation rates of JAKis due to AEs were comparable both in the very elderly group (≥75 years) and the elderly group (65 ≤ years < 75). Whereas chronic lung disease and hypoalbuminemia were independently associated with discontinuation rates due to AEs, the overall drug retention rates were significantly lower in patients treated with the approved dose of JAKis than in those treated with a reduced or tapered dose. Conclusions: Our results suggest that the overall drug retention rate of JAKis in very elderly patients (≥75 years) was comparable with that in elderly patients (65 ≤ years < 75). The discontinuation rates of JAKis due to AEs were also comparable both in very elderly group patients and elderly patients.
format Online
Article
Text
id pubmed-10380728
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103807282023-07-29 Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis Temmoku, Jumpei Miyata, Masayuki Suzuki, Eiji Sumichika, Yuya Saito, Kenji Yoshida, Shuhei Matsumoto, Haruki Fujita, Yuya Matsuoka, Naoki Asano, Tomoyuki Sato, Shuzo Migita, Kiyoshi J Clin Med Article Background: We examined the real-world drug retention rate and safety data of Janus kinase inhibitors (JAKis) in elderly patients with rheumatoid arthritis (RA). Methods: This study enrolled 133 RA patients (≥65 years) with sufficient clinical data who were initiated with JAKis during the study period. These patients were divided into two groups: the very elderly group (≥ 75 years) and the elderly group (65 ≤ years < 75). The drug retention rates of JAKis were compared using Kaplan–Meier curves. Results: The discontinuation rates of JAKis were as follows: lack of effectiveness 27 (20.3%), adverse events (AEs) 29 (21.8%), and remission 2 (1.5%). There was no significant difference in the overall drug retention rate between the very elderly group (≥75 years) and the elderly group. Furthermore, the overall drug retention rates of JAKis were not affected by gender, methotrexate use, and anti-citrullinated protein/peptide antibody (ACPA) status. The discontinuation rates of JAKis due to AEs were comparable both in the very elderly group (≥75 years) and the elderly group (65 ≤ years < 75). Whereas chronic lung disease and hypoalbuminemia were independently associated with discontinuation rates due to AEs, the overall drug retention rates were significantly lower in patients treated with the approved dose of JAKis than in those treated with a reduced or tapered dose. Conclusions: Our results suggest that the overall drug retention rate of JAKis in very elderly patients (≥75 years) was comparable with that in elderly patients (65 ≤ years < 75). The discontinuation rates of JAKis due to AEs were also comparable both in very elderly group patients and elderly patients. MDPI 2023-07-10 /pmc/articles/PMC10380728/ /pubmed/37510700 http://dx.doi.org/10.3390/jcm12144585 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Temmoku, Jumpei
Miyata, Masayuki
Suzuki, Eiji
Sumichika, Yuya
Saito, Kenji
Yoshida, Shuhei
Matsumoto, Haruki
Fujita, Yuya
Matsuoka, Naoki
Asano, Tomoyuki
Sato, Shuzo
Migita, Kiyoshi
Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis
title Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis
title_full Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis
title_fullStr Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis
title_full_unstemmed Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis
title_short Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis
title_sort drug retention rates and the safety of janus kinase inhibitors in elderly patients with rheumatoid arthritis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380728/
https://www.ncbi.nlm.nih.gov/pubmed/37510700
http://dx.doi.org/10.3390/jcm12144585
work_keys_str_mv AT temmokujumpei drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis
AT miyatamasayuki drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis
AT suzukieiji drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis
AT sumichikayuya drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis
AT saitokenji drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis
AT yoshidashuhei drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis
AT matsumotoharuki drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis
AT fujitayuya drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis
AT matsuokanaoki drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis
AT asanotomoyuki drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis
AT satoshuzo drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis
AT migitakiyoshi drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis